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Summary
Background The population impact of pneumococcal conjugate vaccines (PCVs) depends on direct and indirect 
protection. Following Malawi’s introduction of the 13-valent PCV (PCV13) in 2011, we examined its impact on vaccine 
and non-vaccine serotype invasive pneumococcal disease among vaccine-eligible-age and vaccine-ineligible-age 
children and adults.
Methods We did a prospective observational time-series analysis and a case-control study. We used data from between 
Jan 1, 2006, and Dec 31, 2018, from laboratory-based surveillance at a government hospital in Malawi. This period 
included 6 years before and 7 years after introduction of PCV13. By use of negative-binomial regression, we evaluated 
secular trend-adjusted incidence rate ratio (IRR) in vaccine serotype and non-vaccine serotype invasive pneumococcal 
disease before and after introduction of PCV. We compared predicted counterfactual incidence in hypothetical 
absence of vaccine with empirically observed incidence following vaccine introduction. The case-control study 
assessed vaccine effectiveness, comparing PCV uptake among cases of vaccine-eligible-age invasive pneumococcal 
disease versus matched community controls.
Findings Surveillance covered 10 281 476 person-years of observation, with 140 498 blood and 63 291 cerebrospinal 
fluid cultures. A reduction in total (vaccine serotype plus non-vaccine serotype) invasive pneumococcal disease 
incidence preceded introduction of PCV: 19% (IRR 0·81, 95% CI 0·74 to 0·88, p<0·0001) among infants (<1 year old), 
14% (0·86, 0·80 to 0·93, p<0·0001) among children aged 1–4 years, and 8% (0·92, 0·83 to 1·01, p=0·084) among 
adolescents and adults (≥15 years old). Among children aged 5–14 years there was a 2% increase in total invasive 
pneumococcal disease (1·02, 0·93 to 1·11, p=0·72). Compared with the counterfactually predicted incidence, 
incidence of post-PCV13 vaccine serotype invasive pneumococcal disease was 74% (95% CI 70 to 78) lower among 
children aged 1–4 years and 79% (76 to 83)  lower among children aged 5–14 years, but only 38% (37 to 40) lower 
among infants and 47% (44 to 51) lower among adolescents and adults. Although non-vaccine serotype invasive 
pneumococcal disease has increased in incidence since 2015, observed incidence remains low. The case-control study 
(19 cases and 76 controls) showed vaccine effectiveness against vaccine serotype invasive pneumococcal disease 
of 80·7% (–73·7 to 97·9).
Interpretation In a high-mortality, high-HIV-prevalence setting in Africa, there were significant pre-vaccine reductions 
in the incidence of invasive pneumococcal disease. 7 years after PCV introduction, although vaccine-attributable 
impact among vaccine-eligible-age children was significant, indirect effects benefitting unvaccinated infants and adults 
were not. Policy decisions should consider multiple alternative strategies for reducing disease burden, including 
targeted vaccination outside infant Expanded Programme of Immunization to benefit vulnerable populations.
Funding Bill & Melinda Gates Foundation, Wellcome Trust, and National Institute for Health Research.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Streptococcus pneumoniae is estimated to be responsible 
for more than 318 000 deaths per year (uncertainty 
ratio 207 000–395 000) in children aged 1–59 months 
worldwide, with the highest mortality burden in Africa.1 
S pneumoniae has almost 100 serotypes and is a common 
coloniser of the human nasopharynx, particularly in 
young children and resource-poor and HIV-affected 
populations.2 The contribution to adult mortality is 
poorly quantified but large, particularly in older adults 
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and high-risk groups such as individuals with HIV 
infection. Although most carriers are asymptomatic, 
pneumococcal colonisation is a prerequisite for trans-
mission and might also lead to the development of disease, 
including pneumonia, meningitis, and sepsis.
Despite evidence of residual vaccine-serotype carriage 
across sub-Saharan Africa, including Malawi,3,4 vaccine 
trials and post-routine-introduction studies have shown 
the substantial direct protection of pneumococcal conju-
gate vaccines (PCVs) against invasive pneumococcal 
disease incidence among age-eligible children.5,6 In 
many settings, PCVs have also been associated with herd 
protection with resulting reductions in the incidence of 
invasive pneumococcal disease among vaccine-ineligible 
groups through indirect means, presumably through 
their impact on nasopharyngeal carriage and subsequent 
transmission to unvaccinated individuals.6–8 In high-
income countries, groups benefiting from the indirect 
effects of infant vaccination include the very young,9 
older adults,10 and HIV-infected adults.11 However, 
reported replacement disease, with an absolute increase 
in the incidence of non-vaccine serotype invasive 
pneumococcal disease, has eroded the impact seen 
initially after PCV introduction.5,12
In Malawi—a southern African country consistently 
ranked by the World Bank in the lowest income 
category—invasive pneumococcal disease prevalence 
by age closely mirrors HIV prevalence. HIV-infected 
adults remain at high risk of invasive pneumococcal 
disease, so they would probably benefit from PCV 
vaccination.13,14 In 2015, mean HIV prevalence in Malawi 
was 8·8%, reaching 19·8% among urban women.15 Free 
Research in context
Evidence before this study
The PCV (pneumococcal conjugate vaccine) Review of Impact 
Evidence (PRIME) systematic review included 14 databases with 
data from Jan 1, 2010, to Dec 31, 2016, and concluded that PCV 
had had an impact on multiple pneumococcal endpoints. 
However, the existence of few robust data from sub-Saharan 
Africa was highlighted as a gap in knowledge, with only seven of 
the 44 studies included in the invasive pneumococcal disease 
analysis being from Africa. Extrapolating results of studies from 
high-income countries to sub-Saharan African countries is 
problematic.On April 1, 2020, We implemented a targeted 
literature review strategy using PubMed, restricting the search 
to Africa, and incorporating the PRIME search strategy: 
pneumococc* OR “strep* pneumo*” OR “s. pneumo*” OR 
streptococc* AND “invasive pneumococcal disease” OR “IPD” OR 
invasive bacterial disease AND “pneumococcal vaccines” OR 
“vaccines, conjugate” OR “streptococcal vaccines” AND vaccin* 
OR immuniz* OR immunis*. We did not incorporate any 
language or date restrictions. After reviewing 119 articles, 
13 met the inclusion criteria for reporting vaccine impact on 
invasive pneumococcal disease surveillance data. Although 
reports varied in quality, with most reporting administrative 
data on hospital admissions, there was consistent evidence of 
PCV impact on reducing invasive pneumococcal disease. The 
overall reduction in incidence of invasive pneumococcal disease 
ranged from 31% to 85%. Invasive pneumococcal diseases 
caused by vaccine serotypes also decreased incidence of 
substantially, ranging from 35% to 91%. A common reported 
limitation was a short pre-PCV13 (13-valent PCV) observation 
period, which can introduce bias as a consequence of non-
vaccine-associated trends in disease burden—a major issue in 
Africa in the context of substantial improvements in child 
health in the past 20 years.
Added value of this study
We did a large-scale analysis of PCV13 impact on vaccine 
serotype and non-vaccine serotype invasive pneumococcal 
disease incidence based on 13 years of surveillance 
(10 281 476 person-years at risk), including 6 years before 
and 7 years after Malawi’s 2011 introduction of PCV13 into its 
national immunisation programme. The ongoing invasive 
pneumococcal disease surveillance has benefited from stable 
and consistent laboratory methods. We report a long-
standing reduction in invasive pneumococcal disease 
incidence over the 13 years of analysis. These findings address 
knowledge gaps highlighted in the 2017 WHO technical 
expert consultation, with clear evidence of considerable 
PCV-induced reduction of the incidence of vaccine serotype 
invasive pneumococcal disease among children but a lesser 
indirect effect among infants younger than 1 year old and 
individuals aged 15 years or older. Our findings underscore the 
need for a long observation period to understand the impact 
of PCV in a dynamic context.
Implications of all the available evidence
The scale of herd protection after implementation of PCV will 
depend on several factors including vaccine serotype carriage 
prevalence, the proportion of disease caused by vaccine 
serotypes, force of infection, and population structure and 
mixing. This study showed a direct reduction in the incidence 
of invasive pneumococcal disease among children following 
introduction of PCV13, accelerating the pre-existing 
reductions in incidence. However, by contrast with high-
income countries, and despite high vaccination coverage, 
indirect protection among infants and adults was more 
modest. Control of pneumonia and invasive pneumococcal 
disease in young adults with HIV remains necessary in Africa. 
Improving herd protection with alternative vaccine strategies 
(including alternative schedules) needs evaluation as well as 
reconsideration of a policy to vaccinate high-risk adolescents 
and adults.
Articles
www.thelancet.com/lancetgh   Vol 9   July 2021 e991
anti retroviral therapy has been provided in Malawi 
since 2004 through the support of the Global Fund. Life 
expectancy among HIV-infected people has increased 
markedly since antiretroviral therapy was first intro-
duced in 2004 and made widely available in 2006.14,16 
In 2011, Malawi adopted Option B+, whereby all HIV-
infected pregnant or breastfeeding women commence 
lifelong anti retroviral therapy regardless of clinical or 
immunological stage, dramatically reducing mother-to-
child transmission. On Nov 12, 2011, Malawi (previously 
PCV-naive) introduced 13-valent PCV (PCV13) as part of 
the national Expanded Programme of Immunization, 
using a 3+0 schedule (three primary doses [6, 10, and 
14 weeks of age] with no booster dose). A catch-up 
vaccination campaign included infants younger than 
1 year of age at the date of first dose, receiving three 
doses at 1-month intervals. Field studies in Malawi have 
reported high PCV13 uptake of 90–95%,17 similar to the 
92% PCV13 coverage reported by WHO and UNICEF.18 
Furthermore, we have reported good adherence to the 
dosing schedule in Malawi, with the median age at 
first PCV being 6·3 weeks (IQR 4·9–8·1), 11·2 weeks 
(9·1–14·1) at second dose, and 16·4 weeks (11·4–19·5) 
at third dose.4
In Malawi, we have demonstrated the early onset 
of pneumococcal colonisation,19 a high prevalence of 
residual vaccine serotype carriage among children since 
introduction of PCV13 in 2011,4 and persistent high 
prevalence of pneumococcal carriage among HIV-
infected adults receiving antiretroviral therapy.20,21 We 
also projected that the 10-year vaccine serotype carriage 
reduction among 0–9-year-old children will be lower 
than observed in other settings, mainly driven by a high 
local force of infection (the rate by which a certain age 
group of susceptible individuals is infected).22 Here we 
assess the direct impact of PCV13 on vaccine serotype 
invasive pneumococcal disease and its indirect effects 
on vaccine serotype invasive pneumococcal disease 
in populations age-ineligible for vaccination. We have 
leveraged our long-standing and comprehensive 
sentinel invasive bacterial disease surveillance, 
conducted after the introduction of antiretroviral 
therapy, to assess the direct and indirect population 
impact of PCV13 on the incidence of vaccine serotype 
and non-vaccine serotype invasive pneumococcal 
disease across age groups as well as individual vaccine 
effectiveness.
Methods
Study design and participants
We did a prospective observational time-series study to 
determine the incidence of invasive pneumococcal 
disease and a case-control study to estimate vaccine 
effectiveness in age-eligible infants (those aged 6 weeks 
or older on the date of PCV introduction, Nov 12, 2012).
We have conducted ongoing sentinel surveillance for 
laboratory-confirmed invasive pneumococcal disease, 
including bloodstream infection and meningitis among 
all age groups at the Queen Elizabeth Central Hospital 
(QECH), Blantyre, Malawi, since 1998, as described 
previously.23,24 QECH is the government referral hospital 
providing free medical care to the 1·3 million urban, 
peri-urban, and rural residents of Blantyre District. In 
accordance with long-standing clinical guidelines, all 
adults and children presenting to QECH with fever 
(axillary temperature >37·5°C) or clinical evidence of 
sepsis or meningitis undergo blood cultures and, where 
appropriate, lumbar puncture. Although generally stable 
over time, the ratio of blood cultures to population size 
fell after 2006 before increasing again in 2010 and 
thereafter returned to a ratio similar to 2006.23 We report 
data generated after the national introduction of 
antiretroviral therapy, from Jan 1, 2006, to Dec 31, 2018.
The study protocol was approved by Malawi’s National 
Health Sciences Research Committee (protocol 867), 
the University of Malawi College of Medicine Research 
and Ethics Committee (P.01/08/609 and P.09/09/826), 
and the University of Liverpool Research Ethics 
Committee (RETH490). The Centers for Disease Control 
and Prevention relied on the University of Liverpool 
Research Ethics Committee for ethics approval. For the 
case-control component, the parent or guardian of all 
child participants provided written informed consent, 
and children 8 years or older provided written informed 
assent. This consent included consent for publication.
Procedures
Blood and cerebrospinal fluid (CSF) specimens were 
processed at the Malawi–Liverpool–Wellcome Trust 
Clinical Research Programme (co-located with QECH) 
laboratory, using BacT/Alert 3D (Biomerieux; Marcy 
l’Etoile, France). Those positive by BacT/Alert 3D were 
Gram stained and cocci further assessed using the 
catalase test. For subsequent serotyping, archived 
pneumococcal isolates were plated on gentamicin-sheep 
blood agar (SBG; 7% sheep blood, 5 µL gentamicin 
per mL) and incubated overnight at 37°C in 5% CO2. 
S pneumoniae growth was confirmed by colony 
morphology and optochin disc (Oxoid; Basingstoke, UK) 
susceptibility. The bile solubility test was used on isolates 
with no or intermediate (zone diameter <14mm) optochin 
susceptibility. A single colony of confirmed pneumococcus 
with the predominant morphological phenotype was 
selected and grown on a new SBG plate as before. Growth 
from this second plate was used for serotyping by latex 
agglutination (ImmuLex 7-10-13-valent Pneumotest; 
Statens Serum Institute; Copenhagen, Denmark). The 
ImmuLex kit allows for differential identification of each 
PCV13 vaccine serotype but not for differential identifi-
cation of non-vaccine serotypes; therefore, non-vaccine 
serotype and non-typeable isolates were 
reported as non-vaccine serotype. Latex agglutination was 
used on all samples collected after Jan 1, 2014. Serotyping 
based on nucleic acid amplification was performed on 
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samples collected between Jan 1, 2006, and Dec 31, 2013, 
using the Triplex sequential real-time PCR (rtPCR)-
serotyping Africa protocol of the Centers for Disease 
Control and Prevention.25 Both assays have been shown to 
be highly accurate and concordant in pneumococcal sero-
typing.26,27 For identified serogroups that contained 
vaccine serotypes but for which the rtPCR assay did not 
provide serotype differentiation (6A, B, C, and D, 9A and 
V, 18A, B, C, and F, and 7A and F), latex agglutination 
was used to determine vaccine serotype presence. 
A random selection of serotyped isolates was sent 
for confirmatory serotyping by Quellung reaction at 
the regional pneumo coccal reference laboratory at 
the National Institute for Communicable Disease, 
Johannesburg, South Africa. Since Aug 13, 2011, 
serotyping occurs in real time with specimen processing. 
Isolates collected before Aug 13, 2011, were retrospectively 
serotyped. Demographic information was collected at the 
time of sampling from the patient.
Statistical analysis
Demographic characteristics were summarised using 
means, SDs, medians, and IQRs for continuous variables 
and frequency distributions for categorical variables. 
Comparison of covariate distribution between study 
groups was done by χ² test (Mantel-Haenszel χ² where 
stratified), unless there was fewer than five observations 
where Fisher’s exact test was used. Comparisons among 
continuous covariates included t tests of means and 
rank-sum tests of medians.
Invasive pneumococcal disease surveillance at QECH 
(providing care to the 1·3 million residents of Blantyre 
District, with very few inpatient beds outside QECH) 
included systematic recruitment from the whole 
population of Blantyre District. Invasive pneumococcal 
disease events by age category were multiplied by 100 000 
and divided by annual age-specific population estimates 
for Blantyre District published by the Malawi National 
Statistics Office.15 Because not all historical isolates 
were recoverable or serotypeable, we applied each 
year’s proportion of PCV13 vaccine serotype to impute 
vaccine serotype and non-vaccine serotype rates to the 
unserotyped pneumococcal isolates of each year by 
age category. The relative rarity of laboratory-confirmed 
invasive pneumococcal disease make incidence rates 
subject to annual fluctuation even in the presence of 
moderately large surveillance population denominators. 
To account for long-term trends but dampen year-on-year 
fluctuation we used a 3-year locally weighted moving 
average smoother for incidence Î, calculated thus:
where I(t) indicates observed incidence at year t. We 
wexable to consistently identify people who had 
simultaneous meningitis and bacteraemia (ie, with both 
blood and CSF samples collected); thus these episodes 
are potentially double-counted in overall incidence 
calculations. Therefore, we also performed the same 
steps separately for pneumococci derived from blood 
culture and those derived from CSF (appendix p 2).
We evaluated population vaccine coverage in a 
convenience sample of vaccine-eligible-age children 
admitted with diarrhoeal disease to the same institution 
as invasive pneumococcal disease cases. By use of this 
approach we showed that community controls in 
Blantyre and disease-unaligned hospitalised children 
have comparable vaccine coverage.28
To estimate empirically observed invasive pneumo-
coccal disease incidence before and after the 
introduction of PCV13, we fitted negative-binomial 
models, adjusted for time (year of sample collection), to 
smoothed long-term incidence of vaccine serotype and 
non-vaccine serotype invasive pneumococcal disease 
against year and vaccine introduction. To predict the 
counterfactual that would be expected in the period 
Jan 1, 2014–Dec 31, 2018, in the hypothetical absence of 
PCV13, we developed a model that fitted invasive 
pneumococcal disease incidences against year for 
the pre-vaccine period Jan 1, 2006–Dec 31, 2011. 
We compared the predicted counterfactual against 
the same model fitted to the smoothed empirically 
observed incidence for the post-PCV period, Jan 1, 2014–
Dec 31, 2018, excluding the 2 years following PCV13 
introduction, when vaccination coverage among infants 
had not yet plateaued at high population coverage. This 
comparison of empirically observed incidence against 
the counterfactual allowed us to capture not only a step 
change in incidence rate following vaccine, but also a 
change in the rate of reduction in the incidence and 
allowed us to observe whether vaccine introduction 
further enhanced the rate of reduction of an already 
(before PCV introduction) declining incidence. Confi-
dence bounds about the model-derived counterfactual 
were constructed from the negative-binomial model. 
However, because we report all observed cases in the 
population over a period of 13 years rather than a sample 
thereof, we did not calculate an a-priori sample size for 
predefined power. Incidence rate ratios (IRRs) for 
invasive pneumococcal disease were calculated as:
The percent reduction comparing the counterfactually 
predicted incidence of invasive pneumococcal disease 
and the empirically observed incidence of vaccine 
serotype invasive pneumococcal disease was calculated 
as (1 – IRR) × 100.
To estimate vaccine effectiveness from identified 
patients with invasive pneumococcal disease admitted to 
QECH between Nov 12, 2011 and Dec 31, 2016, we selected 
Î=
[It – 1 + 2It + It + 1]
4
incidence estimated by negative binomial model
incidence predicted by the counterfactual model
See Online for appendix
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as study case-patients all children who had vaccine 
serotype invasive pneumococcal disease, who were 
vaccine-age-eligible (ie, born 6 weeks before PCV13 
introduction or later), and whose parents consented to 
participate. We then conducted a random walk method in 
the case-patient’s community to systematically identify 
four otherwise healthy age-matched controls, as described 
previously.29 The age difference was date of birth ±30 days 
among children aged younger than 1 year and ±90 days 
among those 1 year or older. We recorded the date of 
vaccination on the patient-held record (known as a Health 
Passport) among these controls and classified their 
vaccine status as it was on the admission date of the 
matched case. By use of STATA version 13.1, we fitted 
an unadjusted conditional logistic regression model 
comparing vaccine receipt between cases and matched 
controls. Vaccine effectiveness was defined as 1 minus 
the ratio of odds of receiving three doses of PCV13 among 
cases compared with matched controls. We calculated 
that to achieve 80% power at 5% significance to detect 
vaccine effectiveness of 80% against vaccine serotype 
invasive pneumococcal disease with four matched 
controls per case, vaccine uptake among controls of 
60% and correlation of vaccine coverage among cases and 
matched controls of 0·5, we would need 16 cases of 
vaccine serotype invasive pneumococcal disease.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report.
Results
Between Jan 1, 2006, and Dec 31, 2018, surveillance at 
QECH covered 10 281 476 person-years of observation. 
140 498 blood cultures and 63 291 cultures of CSF were 
done, yielding 2638 S pneumoniae-positive cultures. 
Among these isolates, 2005 were serotyped, with 
1133 (57%) being PCV13 vaccine serotype and 872 (43%) 
non-vaccine serotype. Serotyping results, stratified by 
individual serotypes (13 vaccine serotypes and 
non-vaccine serotype) and by age group are shown in the 
appendix (pp 4–18). Analysis of isolates that were and 
were not recoverable showed no statistically significant 
difference in age, gender, or sample type (data not 
shown). All samples sent to the South Africa regional 
pneumococcal reference laboratory for testing by 
Quellung reaction were concordant for confirmatory 
testing.
A reduction in total (vaccine serotype plus non-vaccine 
serotype) invasive pneumococcal disease incidence was 
observed after the national introduction of antiretroviral 
therapy (Jan 1, 2006) and before introduction of PCV13 
(both bacteraemia and meningitis; appendix p 1). The 
reduction in total invasive pneumococcal disease 
incidence was 19% (IRR 0·81, 95% CI 0·74–0·88; 
p<0·0001) among infants, 14% (0·86, 0·80–0·93; 
p<0·0001) among children aged 1–4 years, and 8% (0·92, 
0·83–1·01; p=0·084) among people aged 15 years or 
older. Among children aged 5–14 years there was a 
2% increase in total invasive pneumococcal disease 
(IRR 1·02, 95% CI 0·93–1·11, p=0·72). Pre-PCV 
reductions in vaccine serotype and non-vaccine sero-
type invasive pneumococcal disease followed similar 




Infants 0·81 (0·74–0·88) <0·0001
Children aged 1–4 years 0·86 (0·80–0·93) <0·0001
Children aged 5–14 years 1·02 (0·93–1·11) 0·72
Individuals aged ≥15 years 0·92 (0·83–1·01) 0·084
Vaccine serotype disease
Infants 0·81 (0·72–0·90) <0·0001
Children aged 1–4 years 0·92 (0·83–1·01) 0·068
Children aged 5–14 years 1·01 (0·90–1·13) 0·89
Individuals aged ≥15 years 0·89 (0·81–0·99) 0·030
Non-vaccine serotype disease
Infants 0·80 (0·75–0·86) <0·0001
Children aged 1–4 years 0·78 (0·68–0·90) 0·0010
Children aged 5–14 years 1·04 (0·89–1·21) 0·62
Individuals aged ≥15 years 0·96 (0·85–1·08) 0·49
Data are n (%), unless otherwise specified. *χ² test (Mantel-Haenszel χ² where 
stratified) used for categorical covariates, unless fewer than five observations, 
where Fisher’s exact test used. t test of means and rank-sum test of medians used 
for continuous covariates.
Table 1: Reductions in incidence of invasive pneumococcal disease 
before introduction of 13-valent pneumococcal vaccine (2006–11)
Incidence per 100 000 age-specific population Incidence rate ratio 
(95% CI)
After vaccine, empirical 
(95% CI)
After vaccine, counterfactual 
(95% CI)
Total
Infants 30·62 (30·02–31·23) 49·94 (49·34–50·54) 0·61 (0·61–0·62)
Children aged 1–4 years 7·96 (7·38–8·54) 13·74 (13·15–14·32) 0·58 (0·56–0·60)
Children aged 5–14 years 7·22 (6·57–7·88) 29·69 (29·04–30·35) 0·24 (0·23–0·26)
Individuals aged ≥15 years 10·94 (10·21–11·67) 20·29 (19·56–21·02) 0·54 (0·52–0·56)
Vaccine serotype disease
Infants 15·51 (14·68–16·35) 25·18 (24·35–26·02) 0·62 (0·60–0·63)
Children aged 1–4 years 3·50 (2·80–4·21) 13·29 (12·58–14·00) 0·26 (0·22–0·30)
Children aged 5–14 years 3·76 (2·94–4·57) 18·09 (17·28–18·91) 0·21 (0·17–0·24)
Individuals aged ≥15 years 5·37 (4·61–6·13) 10·18 (9·41–10·94) 0·53 (0·49–0·56)
Non-vaccine serotype disease
Infants 16·17 (15·67–16·68) 24·26 (23·75–24·76) 0·67 (0·66–0·67)
Children aged 1–4 years 4·67 (3·56–5·77) 2·50 (1·39–3·61) 1·87 (1·60–2·56)
Children aged 5–14 years 3·53 (2·44–4·63) 12·27 (11·18–13·36) 0·29 (0·22–0·35)
Individuals aged ≥15 years 5·65 (4·77–6·54) 11·19 (10·30–12·08) 0·51 (0·46–0·54)
Negative binomial regression of locally weighted incidence, adjusted for year.
Table 2: Empirical and counterfactually predicted incidence per 100 000 age-specific population of 
invasive pneumococcal disease after introduction of 13-valent pneumococcal vaccine (2014–18)
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patterns (table 1). Following PCV13 introduction in 
November, 2011, vaccine coverage in the age-eligible 
birth cohort in years 2012, 2013, and 2014 for dose 1 
was 84·6%, 95·1% and 97·5%, for dose 2 was 70·3%, 
90·2% and 96·6%, and for dose 3 was 47·7%, 79·9% and 
90·1%. In the years that followed, coverage of all doses 
exceeded 95%.
Compared with the post-vaccine, counterfactually 
predicted incidence of vaccine serotype invasive pneumo-
coccal disease (ie, in hypothetical absence of vaccine), the 
post-vaccine empirically observed incidence of vaccine 
serotype disease was lower by 38% (95% CI 37–40) among 
infants younger than 1 year, by 74% (70–78) among 
children aged 1–4 years, by 79% (76–83) among children 
aged 5–14 years, and by 47% (44–51) among people aged 
15 years or older (table 2). There was a reduction in the 
absolute numbers of invasive pneumococcal disease 
cases from 2006 to 2018 in all age groups in both vaccine 
serotype and non-vaccine serotype invasive pneumococcal 
disease. When aggregating all ages, for example, there 
was a reduction in confirmed cases of vaccine serotype 
invasive pneumococcal disease from 120 in 2006 to 13 
in 2018 (appendix p 19). Similarly, confirmed cases of 
non-vaccine serotype invasive pneumococcal disease 
decreased from 102 to 14 (appendix p 19).
Since 2015 there has been an increase in the incidence 
of non-vaccine serotype disease, which is now the 
commonest cause of invasive pneumococcal disease and 
led to transient increase in total invasive pneumococcal 
disease in 2015 and 2016. Nonetheless, total invasive 
pneumococcal disease incidence remained low (appendix 
p 1). Among 1–4-year-old and 5–14-year-old children, 
post-vaccine empirically observed incidence of vaccine 
serotype invasive pneumococcal disease was lower than 
was anticipated from the background (counterfactual) 
secular trend (figure). The model also showed a lower 
than anticipated incidence of non-vaccine serotype 
disease among 5–14-year-old children, which cannot be 
attributed to vaccine introduction (figure). Serotype 1 and 
5 dominated in a 5-yearly cycle before vaccine intro-
duction, with a peak still observed in serotype 1 after 
PCV13 introduction (appendix p 3).
Statistically significant reductions in empirically 
observed (non-counterfactual) incidence of vaccine sero-
type invasive pneumococcal disease were seen in 2014–18, 
starting around 2 years after introduction of PCV13 
(appendix p 20). However, similar to the counterfactual 
analysis, reductions in empirically observed incidence 
Figure: Incidence as a 3-year moving average of invasive pneumococcal 
disease incidence per 100 000 age-specific population from Jan 1, 2006, to 
Dec 31, 2018
Shown is vaccine serotype invasive pneumococcal disease in infants (A), 
1–4-year-old children (C) 5–14-year-old children (E), and individuals aged 
15 years and older (G) and non-vaccine serotype invasive pneumococcal 
disease in infants (B), 1–4-year-old children (D) 5–14-year-old children (F), 
and individuals aged 15 years and older (H). Negative binomial model fit for 
Jan 1, 2006, to Dec 31, 2011 (before PCV) and predicted counterfactual 
therefrom for Jan 1, 2014, to Dec 31, 2018 (after PCV). Negative binomial 
model fit for Jan 1, 2014, to Dec 31, 2018. PCV=pneumococcal conjugate 
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were smaller and statistically non-significant among 
individuals younger than 1 year and those 15 years or 
older.
Between Oct 7, 2011, and June 27, 2016, we identified 
34 cases of invasive pneumococcal disease among vaccine-
eligible-age children, including 19 with vaccine serotype 
disease (table 3). We recruited 136 controls, matched 
by age and neighbourhood, between Feb 20, 2012, and 
May 19, 2017. Among 19 cases of vaccine serotype invasive 
pneumococcal disease and their 76 matched controls, 
13 groups (65%) had concordant vaccination status so 
could not contribute statistically to conditional logistic 
regression. Among 37 all-serotype invasive pneumococcal 
disease case-control groupings, 17 (46%) had concordant 
vaccination statuses. Conditional logistic regression of 
PCV13 receipt among vaccine serotype invasive pneumo-
coccal disease cases and their matched controls found an 
odds ratio of 0·19 (95% CI 0·02 to 1·74; p=0·14), equivalent 
to a vaccine effectiveness of 80·7% (95% CI –73·7 to 97·9). 
The final analysis was an unadjusted conditional logistic 
regression; adjusting for anthropometry, household size 
and mother’s vital status did not materially affect the 
outcome (data not shown). Broken down by bacteraemia 
and meningitis, the observed longitudinal patterns 
parallel the overall results (appendix p 2)
Discussion
In this low-income sub-Saharan African population with 
a high burden of disease, in which invasive pneumococcal 
disease incidence was already decreasing, we used 
our robust long-term hospital-based surveillance to show 
a substantial additional reduction in the incidence of 
vaccine serotype invasive pneumococcal disease among 
children aged 1–4 years and 5–14 years following 
introduction of PCV13. Significant reductions in 
incidence did not occur among infants younger than 
1 year and adolescents and adults aged 15 years or older. 
Although, as has been observed elsewhere,30 the power of 
our case-control analysis was undermined by high vaccine 
uptake (the CIs are wide and include 1), our vaccine 
effectiveness point estimate derived from case-control 
analysis suggests protection among vaccine-age-eligible 
children comparable with other post-introduction studies 
in similar populations.5,6 Serotype replacement by non-
vaccine serotype has occurred since introduction of PCV 
but remains low in absolute terms. The more modest 
indirect effects among very young and older people is 
similar to those seen after introduction of PCV in other 
sub-Saharan African countries, including The Gambia5 
and Kenya.6 The reduction in the incidence of non-vaccine 
serotype disease in these age groups suggests a relatively 
small contribution of vaccine to the reduction in the 
incidence of vaccine serotype disease. This is in marked 
contrast to the USA and some European countries, where 
impact on adult vaccine serotype invasive pneumococcal 
disease exceeded that seen among vaccine-eligible age 
groups in absolute terms.31
The absence of greater evidence of indirect protection, 
despite high vaccine coverage in the 7 years following 
introduction of PCV in Malawi, might have several 
causes. Malawi’s accelerated 3+0 vaccine schedule with 
no booster, and a catch-up only among infants younger 
than 1 year, on initial introduction has not led to the 
same reduction in vaccine serotype carriage seen in high-
income settings where schedules frequently include 
doses in the second year of life.4 Older siblings are often 
the source of pneumococcal transmission to younger 
infants in rural Malawi. Owing to a large carriage pool in 
this age group, it might take many years of vaccine rollout 
before its effects are measurable. Additionally, median 
age at first pneumococcal coloni sation is 6–8 weeks of 
age, before receipt of the full course of PCV13.19,32 Once 
colonisation occurs, serotype-specific vaccine effective-
ness could be blunted. Among Malawian adults, invasive 
pneumococcal disease is partially driven by HIV co-
infection. Ubiquitous availability of antiretroviral therapy 
has been temporally associated with reductions in the 
incidence of invasive pneumococcal disease in Malawi,14 
as has occurred in South Africa,33 but similar impact of 
antiretroviral therapy on pneumococcal carriage has not 
been observed.4,20
The improved survival of HIV-infected people on 
antiretroviral therapy contributes to residual vaccine 






Sex ·· ·· 0·22
Male 23 (68%) 69 (51%) ··
Female 11 (32%) 67 (49%) ··





Vaccine record observed 33 (97%) 132 (97%) 0·065
Mean household occupants (SD) 4·3 (1·5) 4·3 (1·4) 0·99
Mean maternal age, years (SD) 25·6 (5·8) 26·5 (6·4) 0·53
Mother deceased 1 (3%) 0 0·21
Father deceased 0 1 (1%) 0·79
Z-score
Weight for age –1·5 0·1 <0·0001
Height for age –0·3 –0·5 0·66
Weight for height –1·8 0·6 <0·0001
Number of pneumcoccal conjugate vaccine doses received
0 6 (18%) 25 (18%) ··
1 6 (18%) 11 (8%) ··
2 5 (15%) 15 (11%) ··
3 17 (50%) 85 (63%) ··
Data are n (%), unless otherwise specified. *χ² test (Mantel-Haenszel χ² where 
stratified) used for categorical covariates, unless fewer than five observations, 
where Fisher’s exact test used. t test of means and rank-sum test of medians used 
for continuous covariates.
Table 3: Demographic features of cases of vaccine-eligible-age 
all-serotype invasive pneumococcal disease and age-matched and 
community-matched controls
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the community, further reducing potential indirect 
vaccine effects. Adults at particularly high risk of 
pneumococcal colonisation and disease (including 
HIV-infected adults) or those whose pneumococcal 
acquisition is derived from other adults might benefit 
less from an infant schedule.34 Although our laboratory 
surveillance did not collect individual HIV status, we 
have reported HIV seroprevalence of 85% among adult 
patients with bacterial meningitis and 78% among those 
with pneumonia.35 This seroprevalence is similar to 
that in South Africa, where 89% of adult invasive 
pneumococcal disease cases were in HIV co-infected 
people, with invasive pneumococcal disease incidence 
much higher than among HIV-uninfected people.34 
Given the persistence of vaccine serotype carriage and 
invasive pneumococcal disease in this vulnerable 
population, the possible benefit of adult vaccination in 
this context should be reconsidered.13,36
Following introduction of 7-valent PCV (PCV7) in Alaska, 
USA, replacement disease was observed.37 More than a 
decade later, similar observations have been made in The 
Gambia,38 the UK,12 and South Africa39 following iterative 
introductions of PCV7 then PCV13. In Malawi, although 
non-vaccine serotype disease events now outnumber 
vaccine serotype events, the absolute number of such 
events is low, and overall burden of all-cause invasive 
pneumococcal disease has decreased. This is probably 
due to concurrent non-vaccine interventions, such as 
availability of antiretroviral therapy, rotavirus vaccination, 
improved control of malaria, and improved nutrition 
security. The cumulative impact of these public health 
measures in reducing the overall burden of all-cause 
invasive pneumococcal disease underlines that no one 
public health intervention (including vaccines) is adequate 
to significantly reduce disease burden. Rather, a strategy 
of implementing multiple public health interventions, 
including a pneumo coccal vaccine that provides both 
direct and indirect protection, is optimal. Ongoing 
serotype-specific surveillance is required to monitor for the 
emergence of non-vaccine serotype disease, particularly 
for isolates that are antimicrobial resistant.
Use of observational data to attribute causality to 
reductions in incidence after introduction of vaccines is 
challenging, particularly given pre-existing reductions.30 
Nonetheless, our surveillance has the advantages of 
being long standing, being methodologically stable, and 
occurring in a stable setting with little risk of a changes in 
treatment-seeking behaviour. The duration and scale of 
reductions in incidence of invasive pneumococcal disease 
before vaccine introduction is missing from many studies 
in Africa. Although reductions in incidence of all-serotype 
invasive pneumococcal disease were observed in Malawi 
well before introduction of PCV13, our data suggest 
a definitive additional benefit of vaccination. In age 
groups enriched for vaccine-eligible-age children where 
there have been high rates of vaccine uptake, invasive 
pneumococcal disease incidence reduced faster and was 
lower following vaccine introduction than anticipated 
from secular trends alone.
Although this work provides a robust estimate of 
vaccine impact, it has several limitations. We were not 
able to correct for episodes of concurrent bacteraemia 
and meningitis, but we suspect this number is small and 
consistent over time and unlikely to introduce substantial 
bias. A vaccine with high uptake and even moderate 
impact within a population can undermine the ability 
to assess its effectiveness in individual recipients using 
a case-control design. The estimated vaccine uptake 
of 60% among controls for the purpose of sample 
size calculation was too conservative, given Malawi’s 
successful rapid PCV13 roll out and high coverage. 
This smaller sample size challenged the analytical power 
of the matched case-control study which requires 
discordance in coverage. A successful vaccine decreases 
risk of disease, which, together with the long-standing 
gradual reductions in invasive pneumococcal disease 
incidence, made it difficult to recruit sufficient vaccine-
eligible-age cases of vaccine serotype invasive pneumo-
coccal disease for the case-control study.30 The resulting 
insufficient recruitment of cases led to the case-control 
study being underpowered. In populations with high 
vaccine coverage, there is always a concern about the 
comparability of unvaccinated individuals with those 
who are vaccinated. Notwithstanding these limitations, 
taken together the observed impact and effectiveness are 
consistent in suggesting substantial reductions in risk 
of vaccine serotype invasive pneumococcal disease in 
Malawi among vaccine-eligible age groups.
In conclusion, even with pre-existing reductions 
in the incidence of invasive pneumococcal disease, the 
introduction of a 3+0 PCV13 infant schedule in Malawi 
has led to a substantial reduction in the incidence of 
invasive pneumococcal disease among vaccine-eligible-
age children. However, despite high vaccination coverage 
and adequate time since PCV introduction, indirect 
protection among adolescents and adults has been 
more muted, especially in contrast with that seen in 
high-income countries. A trend of decreasing invasive 
pneumococcal disease incidence before introduction 
of PCV further underlines the need for a strategy of 
implementing multiple public health interventions 
to substantially reduce disease burden. Nonetheless, 
as improvements in available vaccine interventions 
arise, including alternative schedules and extended-
spectrum vaccines at reduced costs, consideration should 
be given to evaluating PCV vaccination among high-risk 
populations, including HIV-infected adults, in settings 
with high force of infection and disease burden.
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